Nestlé Health Sciences completes acquisition of CM&D Pharma

LUTRY, Switzerland — Nestlé Health Sciences completed its acquisition of a company that develops "medical foods" for such medical conditions as kidney disease, inflammatory bowel disease and colon cancer.

The acquisition of CM&D Pharma comes one month after Nestlé Health Sciences became operational. The company said the acquisition would boost its science-based nutrition ventures. CM&D’s leading product, Fostrap, is a medical food in the form of a chewing gum for kidney patients who have an elevated level of phosphate in the blood, known as hyperphosphatemia.

Financial terms were not disclosed.